The application of EDTA in drug delivery systems: Doxorubicin liposomes loaded via NH4EDTA gradient

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3611-3621

  Song, Yanzhi ^a   Huang, Zhenjun ^a   Song, Yang ^b   Tian, Qingjing ^a   Liu, Xinrong ^a   She, Zhennan ^a   Jiao, Jiao ^a   Lu, Eliza ^c   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Hansoh Pharmaceutical Co Ltd   (China)

^c Livzon Mabpharm Inc   (China)

Author keywords

Antitumor activity; Doxorubicin; Ion gradient; Liposome; Toxicity

Indexed keywords

CHELATING AGENT; DOXORUBICIN; LIPOSOME; TETRAAMMONIUM EDETATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EDETIC ACID; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARDIOTOXICITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DELAYED DRUG RELEASE; DOSE RESPONSE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; ENCAPSULATION; LIPOSOMAL DELIVERY; LIVER CANCER; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HEART; HEART MUSCLE; PATHOLOGY; PROCEDURES; SOLUBILITY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EDETIC ACID; HEART; LIPOSOMES; MALE; MICE; MYOCARDIUM; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SOLUBILITY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905505200     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S64602     Document Type: Article

References (40)

1. Domingo JL. Developmental toxicity of metal chelating agents. Reprod Toxicol. 1998;12(5):499-510.
2. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010;7(7):2745-2788.
3. Gordon GF. EDTA and Chelation Therapy: History and Mechanisms of Action. Payson, AZ: Gordon Research Institute; 2000.
4. Riordan HD, Cheraskin E, Dirks M. Mineral excretion associated with EDTA chelation therapy. Journal of Advancement in Medicine. 1990;3(2):111-123.
5. Waters RS, Bryden NA, Patterson KY, Veillon C, Anderson RA. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res. 2001;83(3):207-221.
6. Born T, Kontoghiorghe CN, Spyrou A, Kolnagou A, Kontoghiorghes GJ. EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/ benefit assessment. Toxicol Mech Methods. 2013;23(1):11-17.
7. Clarke NE. Atherosclerosis, occlusive vascular disease, and EDTA. Am J Cardiol. 1960;6(2):233-236.
8. Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease [review]. Cochrane Database Syst Rev. 2002;4:CD002785.
9. Kitchell JR, Palmon F Jr, Aytan N, Meltzer LE. The treatment of coronary artery disease with disodium EDTA: a reappraisal. Am J Cardiol. 1963;11(4):501-506.
10. Blumer W, Cranton EM. Ninety percent reduction in cancer mortality after EDTA chelation therapy with EDTA. Journal of Advancement in Medicine. 1989;2(1-2):183-188.
11. Seely DM, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc Disord. 2005;5:32.
12. Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem. 2003;10(12):1021-1034.
13. Cranton EM, Frackelton JP. Free oxygen radical pathology and EDTA chelation therapy: mechanisms of action. Journal of Advancement in Medicine. 1998;11(4):277-310.
14. Hucho F, Kogler H, Pribilla I, Schiebler W, Tripier D. Inventors; Hoechst Aktiengesellschaft, assignee. Use of ethylenediaminetetraacetic acid as inhibitor of calcium/calmoduline-dependent protein kinase II or protein kinase C. European patent CA2002637 A1. 1990 May 10.
15. Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med. 1997;103(2):134-145.
16. Body JJ. Bone metastases and tumor-induced hypercalcemia. Curr Opin Oncol. 1992;4(4):624-631.
17. Abdi S, Ali A. Role of ROS modified human DNA in the pathogenesis and etiology of cancer. Cancer Lett. 1999;142(1):1-9.
18. Martinez-Cayuela M. Oxygen free radicals and human disease. Bio-chimie. 1995;77(3):147-161.
19. Thompson KA, Goodale DB. The recent development of propofol (Diprivan®). Intensive Care Med. 2000;26(Suppl 4):S400-S404.
20. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19(6):670-686.
21. Basser RL, Green MD. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev. 1993;19(1):57-77.
22. Dudka J, Burdan F, Korga A, et al. Intensification of doxorubicin- related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase. Oxid Med Cell Longev. 2012;2012:139327.
23. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006;41(3): 389-405.
24. Ortega R, Deves G, Bohic S, Simionovici A, Ménez B, Bonnin- Mosbah M. Iron distribution in cancer cells following doxorubicin exposure using proton and X-ray synchrotron radiation microprobes. Nucl Instrum Methods Phys Res B. 2001;181(1):480-484.
25. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213-1225.
26. Chen Y, Wan Y, Wang Y, Zhang H, Jiao Z. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine. 2011;6:2321-2326.
27. Dudka J, Gieroba R, Korga A, et al. Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med. 2012;2012:606183.
28. Hruby M, Konak C, Ulbrich K. Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J Control Release. 2005;103(1): 137-148.
29. Mitra S, Gaur U, Ghosh P, Maitra A. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release. 2001;74(1-3):317-323.
30. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs. 1997;54 (Suppl 4):15-21.
31. Gubernator J, Chwastek G, Korycinska M, et al. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J Control Release. 2010;146(1):68-75.
32. Yang Y, Ma Y, Wang S. A novel method to load topotecan into liposomes driven by a transmembrane NH4EDTA gradient. Eur J Pharm Biopharm. 2012;80(2):332-339.
33. Cui J, Li C, Guo W, et al. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J Control Release. 2007;118(2):204-215.
34. Li X, Hirsh DJ, Cabral-Lilly D, et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta. 1998;1415(1):23-40.
35. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151(2): 201-215.
36. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006;1758(10):1633-1640.
37. Mei L, Decker EA, McClements DJ. Evidence of iron association with emulsion droplets and its impact on lipid oxidation. J Agric Food Chem. 1998;46(12):5072-5077.
38. Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol. 2004;18(2):219-230.
39. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol. 2004;378:340-361.
40. Dugi D, Takemoto A. The role of heavy metal detoxification in heart disease and cancers: a pilot study in detoxification of heavy metals. Paper presented at: WESCON Biomedicine and Bioengineering Conference; September 24, 2002; Anaheim, CA, USA